Featured Articles

  1. Ribobay Pharma Boosts CRDMO Offerings With Cytiva's First FlexFactory Platform For Oligonucleotides 5/15/2024

    Ribobay Pharma, a leading Chinese biopharmaceutical contract research, development, and manufacturing organization (CRDMO) and a spin-off company of General Biol (Anhui) Co., Ltd, will provide cGMP-level oligonucleotide (oligo) CRDMO services to the world using Cytiva’s first FlexFactory platform for oligo manufacturing.

  2. Viral Vector Producer Cell Lines: Learning From mAbs 5/7/2024

    Learn how applying bioprocessing knowledge from the production of mAbs can accelerate the development of viral vector cell lines and improve efficiency in gene therapy manufacturing.

  3. Nucleic Acid Therapeutics And Environmental Impact 4/11/2024

    Nucleic acid therapeutics offer exciting new avenues of treatment. Learn about the history of nucleic acid therapeutics and the environmental impact of manufacturing mRNA and oligonucleotides.

  4. The Smart, Savvy Science Driving Viral Vector Scale-Up 4/8/2024

    Learn about cutting-edge strategies, including alternatives to plasmid-based transient transfection, aimed at addressing current process challenges and bringing revolutionary treatments to patients in need.

  5. Top Challenges In Recombinant Protein Purification Process Development 3/27/2024

    Get insights from process developers working with recombinant proteins that cannot be purified with affinity chromatography.

  6. Building Biopharma Resilience In Developing Gene Therapies 3/21/2024

    Learn about the opportunities and challenges surrounding gene therapies, the importance of collaboration between biopharma startups and academia, difficulties with the talent pipeline, and more.

  7. Biopharmaceuticals: State Of The Industry 3/21/2024

    How are government policies, talent pools, and supply chain constraints affecting the state of the industry? Learn about the biopharma industry’s biggest strengths, greatest challenges, and much more.

  8. Biopharma Resilience: Mass Immunization Programs 3/21/2024

    Explore the challenges involved with mass immunization programs, what role government can play in facilitating vaccination programs, how technology is transforming the biopharma industry, and more.

  9. Manufacturing Challenges With High Concentration Biologics 3/18/2024

    Explore key process operations, some of the challenges in manufacturing high-concentration biologics, and factors to consider for process optimization.

  10. High-Concentration Drug Manufacturing Challenges And Opportunities 3/18/2024

    The demand for high-concentration/subcutaneous drugs is on the rise. Explore opportunities for enhancing your biotech drug production platform.